This study is currently being conducted at ten centers in the United States. If patients are qualified for the study, they are treated with study drug once a week for four weeks, and then followed by the site staff for an additional two months. There are a total of 15 study visits over twelve weeks, for which patients can be compensated for their time and travel.
Lisa Beck, MD – University of Rochester, Department of Dermatology
Deidre Stonestreet – Sr. Project Manager – i3, an Inventiv Healthcare Company